PARP inhibition induces BAX/BAK‐independent synthetic lethality of BRCA1‐deficient non‐small cell lung cancer
Ian Paul(Queen's University Belfast), Dean A. Fennell(University of Leicester), Jaine K. Blayney(Queen's University Belfast), Kenneth J. O’Byrne(Translational Research Institute), Jacqueline A. James(Queen's University Belfast), Kienan I. Savage(Queen's University Belfast), E Lamers(Queen's University Belfast), Derek J. Richard(Queensland University of Technology), Michael Sheaff(Moorfields Eye Hospital NHS Foundation Trust), Peter W. Hamilton(Queen's University Belfast), D. Paul Harkin(Almac (United Kingdom)), Keith M. Kerr(University of Aberdeen), Jennifer E. Quinn(Queen's University Belfast), Kathy Gately(Trinity College Dublin)
Cited by 35
Related Papers
QuPath: Open source software for digital pathology image analysis
|Scientific Reports|2017|8.9k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k